- Clinical trial supply management covers the investigational product from forecast to destruction, with a record at each step.
- ICH E6(R3), in force in the EU since July 23, 2025, asks sponsors to supply sites without interrupting treatment.
- Set a trigger level and a resupply quantity per site, based on its recruitment rate and shipping time.
- Kit numbers keep the blind: the system picks the kit, and the site never sees the treatment arm.
- 76% of protocols go through at least one amendment (Tufts CSDD, 2024), and each dose change reshapes the supply plan.
A site that runs out of kits cannot randomize its next patient. A site that holds too many watches them expire on the shelf. Clinical trial supply management sits between those two failures, and it gets harder with every amendment: a Tufts CSDD study published in 2024 found that 76% of phase I to IV protocols go through at least one amendment, with an average of 3.3 amendments per protocol. A dose change or a new arm means new kit types, new labels and a new forecast, often while sites still dispense the old ones. This guide walks through each stage, what regulators expect you to record, and the decisions to take before the first patient is randomized.
What is clinical trial supply management?
Clinical trial supply management is the planning, tracking and delivery of investigational product to sites and participants, from the first forecast to the final destruction of unused kits. It covers packaging and labeling, blinding, depots, site resupply, expiry and temperature control, dispensing, and accountability. Each stage leaves a record that an inspector can trace back to a participant.
The investigational product includes the drug under study, the active comparator and the placebo. In a device investigation, the same logic applies to investigational devices. The table below follows a kit through its life in a study.
| Stage | What you decide | What you record |
|---|---|---|
| Forecast | Quantities per arm, from the recruitment plan, visit schedule and dose | Forecast assumptions and their updates |
| Packaging and labeling | Kit types, label text, blinded kit numbers | Batch numbers, expiry dates, kit lists |
| Depots | Where stock sits and how long a shipment takes to each site | Depot inventory and shipments |
| Site resupply | Trigger level and resupply quantity per site | Shipment, receipt date, condition on arrival |
| Dispensing | Which kit goes to which participant at which visit | Kit number, participant, date, user |
| Returns and destruction | Retrieval of unused product at close-out | Returns, reconciliation, destruction or other disposition |
What do ICH E6(R3) and the FDA require for trial supply?
ICH E6(R3), adopted in January 2025 and applied in the EU since July 23, 2025, makes the sponsor responsible for timely supply, so that no site interrupts a participant's treatment. The sponsor keeps records of the identity, shipment, receipt, return and destruction of the product. The investigator keeps records of delivery, inventory and use by each participant.
The guideline does not impose a shipping model. Section 3.15.3 lets sponsors adapt shipping and dispensing to the product's characteristics, its route of administration and what is already known about its safety. It also asks the sponsor to make sure the product is used only within its current shelf life. The FDA adopted E6(R3) as final guidance on September 8, 2025, and its regulations already set record requirements for drugs and devices.
| Source | Who | What must be recorded |
|---|---|---|
| ICH E6(R3), section 3.15.3 | Sponsor | Identity, shipment, receipt, return, destruction or other disposition |
| ICH E6(R3), section 2.10.4 | Investigator or pharmacist | Delivery, inventory, use by each participant, return; dates, quantities, batch numbers, expiry dates, kit and participant codes |
| 21 CFR 312.57(a) | Sponsor (drugs, US) | Receipt, shipment or other disposition; investigator, date, quantity, batch or code mark of each shipment |
| 21 CFR 312.62(a) | Investigator (drugs, US) | Disposition of the drug: dates, quantity, use by subjects |
| 21 CFR 812.140(a)(2) | Investigator (devices, US) | Receipt, use or disposition of each device: type, quantity, batch, who handled it, why units were returned |
A spreadsheet can hold these records for a single-site study. With ten sites, three depots and a monitor who checks accountability at each visit, the same spreadsheet becomes the place where discrepancies start.
How do you decide how much stock each site needs?
You set two numbers per site: a trigger level, below which a shipment leaves the depot, and a resupply quantity, which covers the patients the site will see before the next shipment arrives. Both depend on the site's recruitment rate, the kits each participant uses between shipments, and the shipping time from the depot.
Start the forecast from the recruitment plan, the visit schedule, the dose per arm and the randomization ratio. Add a buffer for screen failures and damaged kits. Then review the levels as recruitment moves. Take two sites in the same study: one randomizes ten participants a month, the other one. A single stock level either leaves the first site short or fills the second site's shelf with kits that will expire before anyone uses them.
Expiry and temperature add two constraints. Block kits close to expiry from dispensing, and quarantine kits after a temperature excursion until the sponsor releases them in writing. The step-by-step guide to forecasting and resupplying sites covers trigger levels and excursions in more detail.
How does supply connect to randomization and the blind?
In a blinded study, the randomization system assigns the participant to an arm and selects a kit for that arm, and the site sees only a kit number. Supply and randomization therefore share one record: a kit list that reveals arm codes, or a resupply done by hand, can break the blind for everyone who reads it.
ICH E6(R3) section 3.15.2 asks for three safeguards in blinded trials: a process to prevent and detect inappropriate unblinding, a mechanism that lets the investigator identify a participant's treatment in a medical emergency without revealing anyone else's, and protection of the blind when a case is unblinded for safety reporting.
Three practices follow from it. Label kits with numbers that carry no arm information. Let the system choose the kit at randomization, so that no one at the site picks from the shelf. Give the permission to see which kit type matches which arm to a role that never meets participants. The article on randomization and supply systems explains how the two functions work together, and the guide to randomizing patients covers the allocation side.
What happens to supply when the protocol changes?
An amendment that changes the dose, adds an arm or extends treatment creates new kit types and new forecasts, while sites keep dispensing under the previous version until their approvals arrive. Tufts CSDD measured in 2024 that sites operate with different protocol versions for 215 days on average.
During those months, two kit types can coexist at the same site: the old dose for participants still under the previous version, and the new dose for those under the amended one. Your system has to know which kit type belongs to which protocol version and which treatment period, or the site coordinator makes that choice by hand at each visit.
Plan for it at set-up. Map kit types to arms and to treatment periods, not to the study as a whole. Keep each site's stock levels editable without rebuilding the study. When the shelf life of a batch is extended, record the new expiry date in the system before relabeled kits are dispensed. In the same study, the Tufts CSDD study of 950 protocols reports that the time from identifying the need to amend to the last approval averages 260 days.
When does a study need a supply module instead of a spreadsheet?
A spreadsheet holds for an open-label, single-site study with one kit type and a long shelf life. Once the study is blinded, runs across several sites or countries, or ships product with a short expiry, a supply module linked to randomization removes manual steps where allocation errors and stock-outs start.
| Situation | Spreadsheet and email | Supply module linked to randomization |
|---|---|---|
| Open-label, single site, one kit type | Workable | Optional |
| Blinded study | Kit list with arm codes at risk of circulating | Site sees kit numbers only |
| Several sites or countries | One missed email stops randomization at a site | Trigger levels per site, alerts on low stock |
| Short shelf life or cold chain | Expiry checked by hand at each visit | Kits close to expiry blocked from dispensing |
| Protocol amendment with a new dose | Two kit lists to reconcile | Kit types mapped to arms and periods |
| Close-out and inspection | Accountability rebuilt from several files | Each allocation recorded with participant, user and time |
The threshold depends less on study size than on the blind and the number of sites. An investigator-led academic trial with two blinded arms across six hospitals needs the same controls as an industry phase II. A medical device investigation that ships units to several sites faces the same accountability questions, under 21 CFR 812.140 in the US.
[[cta]]
How Datacapt handles trial supply
Datacapt Trial Supply Management runs inside the same platform as the EDC and randomization. You create kit types, map them to treatment arms and periods, and import each site's kit list with batch numbers and expiry dates. A site user clicks Allocate in the eCRF and receives the next available kit stored at that site.
Each kit moves through five statuses: In transfer, Received, Available, Allocated and Invalid. When a kit is damaged or goes through a temperature excursion, the site declares it invalid and gives the reason. Datacapt records the participant, the user and the time of each allocation, and sends alerts on low inventory and approaching expiry. Two permissions protect the blind, Subject ID visibility and Kit Type visibility, and you give them to different roles.
Because supply shares the participant record with the eCRF and randomization, no reconciliation step sits between the allocation list and the dispensing log at database lock. You can see the module on the Trial Supply Management page.
Supply decisions to take before the first patient
Clinical trial supply management goes wrong in the gap between three teams: the statistician who writes the randomization scheme, the supply manager who orders the kits, and the study manager who opens the sites. Before the first patient is randomized, put four decisions in writing: the trigger level and resupply quantity for each site, the rule for kits close to expiry, the role that may see kit types, and the way kit types map to treatment periods if the protocol changes. Review the first two once the first sites have recruited for a month.
Frequently asked questions
[[faq]]
Sources
- ICH, ICH E6(R3) Guideline for Good Clinical Practice, Step 4 final version, 2025
- US Code of Federal Regulations, 21 CFR 312.57, Recordkeeping and record retention, current version
- US Code of Federal Regulations, 21 CFR 312.62, Investigator recordkeeping and record retention, current version
- US Code of Federal Regulations, 21 CFR 812.140, Records, current version
- Getz K., Smith Z., Botto E., Murphy E., Dauchy A. (Tufts CSDD), New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance, Therapeutic Innovation & Regulatory Science, 2024
What is the difference between trial supply management and an RTSM?
Trial supply management is the process: forecasting, packaging, shipping, dispensing and accounting for investigational product. An RTSM, for Randomization and Trial Supply Management, is the system that runs randomization and supply in one record. A study can manage supply with spreadsheets, but a blinded multi-site study usually runs it through an RTSM.
Who is responsible for investigational product accountability?
Under ICH E6(R3), the sponsor keeps records of the product's identity, shipment, receipt, return and destruction, and the investigator or pharmacist keeps records of delivery, inventory and use by each participant. In the US, 21 CFR 312.57 and 312.62 set the same split for drugs, and 21 CFR 812.140 covers investigational devices.
How do you set the resupply trigger for a site?
Start from the site's expected participants per month, the kits each participant uses between shipments, and the shipping time from the depot. The trigger covers demand during the shipping time plus a buffer for screen failures and damaged kits. Review it once the site has recruited for a few weeks, since actual recruitment rarely matches the plan.
What happens to unused investigational product at the end of a trial?
The sponsor retrieves unused product from sites and participants, reconciles it against dispensing records, and organizes its return and destruction or another authorized disposition. ICH E6(R3) section 3.15.3 asks the sponsor to keep a documented process for this retrieval and for the disposition of unused product.
With over 10 years of experience working in CROs, Khalil brings deep expertise in clinical trials and a clear understanding of the daily challenges faced by research professionals. His insights are grounded in real-world operations, making his perspective both practical and strategic.
Blog & News Datacapt
News, Articles, Resources et Tutorials.
